Osstell helps dentists and dental surgeons worldwide who want to provide safer, more effective and more successful implant treatment.
Osstell is the global leader in implant stability measurement and osseointegration progress monitoring. Osstell was formed in 1999 to commercialize an invention using Resonance Frequency Analysis (RFA) to determine the clinical status of a dental implant.
Osstell’s proprietary and patented technology helps its customers, dentists around the world, to make dental implant treatments safer, and to increase patient confidence and comfort, by measuring the stability of implants objectively and non-invasively using the ISQ scale (Implant Stability Quotient). More than 860 scientific publications confirm the benefits of the technology, its clinical value, and the use of the ISQ scale for dentists in their daily practices. Osstell is headquartered in Gothenburg, Sweden – the birthplace of dental implants.
Professor and Chairman, Dept. of Oral Surgery and Stomatology, School of Dental Medicine, University of Bern, Switzerland
Oral & Maxillofacial Surgeon, Professor, Oral & Maxillofacial Surgery, UCLA, Los Angeles, USA, Director, Implant Dentistry
DDS, Board Certified Prosthodontist
CEO, Chief of Staff, Dagnelid Clinic & Falkenberg Clinic, SAACD AB
CEO, European Dental Academy
Professor in Prosthodontics, University of Queensland, Brisbane, Australia
Chairman of the Board
Extensive experience in the healthcare sector with leading positions in fast-growing companies such as Mölnlycke, Nobel Biocare, Capio and Unfors RaySafe.
Board member at Unident, Bellman&Symfon and SciBase. Chairman of the Board at GHP Speciality Care and Vitrolife.
18 years’ experience in the private
equity and venture capital market,
most recently as CEO of Bure Equity.
at Fouriertransform, Board
member at Pelly, Jobro
Plåtkomponenter, Cede group,
Partner at Layline Partners, prior to that Investment Manager at Bure Equity, Strategy Consultant at Adera and Management Consultant at McKinsey.
Founder and partner at
Current and previous involvement include companies such as Citat, Bure, Sportmanship, Unfors Raysafe, Start Communication, Rubrik, More Space, Nute, More PR, Imatech Industri & Marin, Unident AB, SGP, and Sjätte AP-fonden.
Visionary entrepreneur founded Unfors RaySafe AB in 1994 and co-founded RTI Electronics AB in the early eighties, both heavily world-wide oriented. Has extensive experience in developing measuring instruments, including several patents.
Nicole Winitsky is currently working as a prosthodontist at the Eastman institute, Folktandvården, Stockholm, Sweden with special focus in prosthodontics in children and young adults diagnosed with diseases affecting their dental development. She is a PhD student at the Karolinska Institute with the research project “Implants in the anterior maxilla in young adults”
She is a frequent lecturer at both national and international symposium, meetings and courses.
More than 20 years of experience in the life science and MedTech industry with leading and CEO positions in growth companies such as Applied Biosystems, Kovalent, Cellectricon and Mentice.
Board member at Leading Light AB
Global Sales Director
Global Marketing Director
VP Product Solutions
Production Supply & Support Director, QA/RA
"Osstell use is critical for my implant practice. Every year, this device more than pays for itself as there are always several patients who heal slowly or who have implants placed with extremely low insertion torque. This confounds my ability to predict when healing has been adequate to proceed to the restorative phase. Osstell provides me with quantitative information necessary to make informed decisions. No longer am I the villain who slows up patient care, but it is objective data about the patient’s healing that becomes the determining factor."
"Osstell is an essential part of my implant practice. As a surgical prosthodontist I use it on every implant case to determine and document implant stability. ISQ values provide the confidence (based on science) to know when each implant is ready to load, whether for immediate or delayed restoration, helping to achieve a successful restorative outcome for each and every patient."
"We are currently using Osstell when we place all implants to establish a baseline measurement of implant stability. At the time of placement if the ISQ is too low (depending on the location - anything below 45) we will remove the fixture, possibly graft and then wait another 3-6 months before trying to place another fixture."
"Since we began using this device in 2009, our decision making process has become more simple and objective. We will continue to use the Osstell values to help guide treatment decisions and as a communication tool with our referring dentists."
"In daily practice, we never measure the insertion torque since we use Osstell instead to monitor implant stability. For non-splinted implants, we want the second ISQ value to be ≥70 to initiate the prosthetic rehabilitation with functional loading. In most implant patients, this is either at 4 or 8 weeks of healing allowing an early loading protocol."
"Comparative surgical and pre-prosthetic Osstell readings provides an effective foundation for shared responsibility between the patient, surgeon and restorative dentist regarding implant integration status. As the team enters the prosthetic phase of treatment objectives, implant performance data helps to focus outcomes based on realistic expectations."
"Osstell has become my personal guide in determining the appropriate time to load patients’ implants, and I now use it for every implant case."
"As a surgical specialist, I work closely with my restorative colleagues. When immediate and early loading treatment is selected, I need certainty in communicating implant stability. Osstell ISQ gives me a “number” I can provide as a tangible measurement of stability. If changes in loading protocols are appropriate, I can provide a numerical value that makes sense and keeps all members of the team on the same page. I value this technology and feel it has only just begun to demonstrate all of its applications in clinical practice."